Founded in 2006, Sagent Pharmaceuticals is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing high-quality injectable products. Our specific product focus is on anti-infectives, oncolytics and critical care, while our initial drug delivery focus is on pre-filled syringes and pre-mixed bags.

Sagent has created a unique, global network of resources, comprising an advanced development network of more than 20 partners, an unparalleled breadth and depth in product manufacturing with more than 60 facilities and access to advanced scientific resources with more than 1,400 R&D employees worldwide.

The company currently has more than 200 products in development with more than 30 submissions to the U.S. Food and Drug Administration (FDA) expected by the end of 2007 and with FDA submissions expected to double in 2008.

Of specific note, Sagent recently raised $53 million in venture funding in a Series A financing.

Led by an executive management team that averages more than 20 years' experience and success in developing and commercializing specialty injectable products, Sagent is redefining the role of a valued, sustainable partner.

Investor Contact:
Ron Pauli, Chief Financial Officer
847-908-1604
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Media Contact:
Geoff Curtis, WeissComm Partners
312-284-4701